よむ、つかう、まなぶ。
資料4 シクロホスファミド水和物 (37 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/shingi2/0000198856_00027.html |
| 出典情報 | 医療上の必要性の高い未承認薬・適応外薬検討会議（第55回 5／31）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
18） Mehta RS, et al. Composite GRFS and CRFS outcomes after adult alternative donor HCT. J Clin
Oncol 2020; 38: 2062-76.
19） Rashidi A, et al. Outcomes of haploidentical vs matched sibling transplantation for
acute myeloid leukemia in first complete remission. Blood Adv 2019; 3: 1826-36.
20） Ahmed S, et al. Lower graft-versus-host disease and relapse risk in post-transplant
cyclophosphamide-based haploidentical versus matched sibling donor reduced-intensity
conditioning transplant for Hodgkin lymphoma. Biol Blood Marrow Transplant 2019; 25: 185968.
21） Ghosh N, et al. Reduced-intensity transplantation for lymphomas using haploidentical related
donors versus HLA-matched sibling donors: A center for international blood and marrow
transplant research analysis. J Clin Oncol 2016; 34: 3141-9.
22） Kanate AS, et al. Reduced-intensity transplantation for lymphomas using haploidentical related
donors vs HLA-matched unrelated donors. Blood 2016; 127: 938-47.
23） Ciurea SO, et al. Haploidentical transplant with posttransplant cyclophosphamide vs matched
unrelated donor transplant for acute myeloid leukemia. Blood 2015; 126: 1033-40.
24） Solomon SR, et al. Myeloablative vs reduced intensity T-cell-replete haploidentical
transplantation for hematologic malignancy. Blood Adv 2019; 3: 2836-44.
25） Bashey A, et al. Mobilized peripheral blood stem cells versus unstimulated bone marrow as a
graft source for T-cell-replete haploidentical donor transplantation using post-transplant
cyclophosphamide. J Clin Oncol 2017; 35: 3002-9.
26） Chiusolo P, et al. A modified post-transplant cyclophosphamide regimen, for unmanipulated
haploidentical marrow transplantation, in acute myeloid leukemia: A multicenter study. Biol
Blood Marrow Transplant 2018; 24: 1243-9.
27） Bazarbachi A, et. al. Haploidentical transplantation with post-transplantation cyclophosphamide
for T cell acute lymphoblastic leukemia: A report from the European Society for Blood and
Marrow Transplantation Acute Leukemia Working Party. Biol Blood Marrow Transplant 2020;
26: 936-42.
28） Nagler A, et.al. Outcome of haploidentical versus matched sibling donors in hematopoietic stem
cell transplantation for adult patients with acute lymphoblastic leukemia: A study from the Acute
Leukemia Working Party of the European Society for Blood and Marrow Transplantation. J
Hemotol Oncol 2021; 14: 53.
29） George B, et.al. Haploidentical transplantation is feasible and associated with reasonable
outcomes despite major infective complications-A single center experience from India.
Transplant Cell Ther 2022; 28: 45.e1-8.
30） Jaiswal SR, et al. Haploidentical peripheral blood stem cell transplantation with posttransplantation cyclophosphamide in children with advanced acute leukemia with fludarabine-,
busulfan-, and melphalan-based conditioning. Biol Blood Marrow Transplant 2016; 22: 499-
37
Oncol 2020; 38: 2062-76.
19） Rashidi A, et al. Outcomes of haploidentical vs matched sibling transplantation for
acute myeloid leukemia in first complete remission. Blood Adv 2019; 3: 1826-36.
20） Ahmed S, et al. Lower graft-versus-host disease and relapse risk in post-transplant
cyclophosphamide-based haploidentical versus matched sibling donor reduced-intensity
conditioning transplant for Hodgkin lymphoma. Biol Blood Marrow Transplant 2019; 25: 185968.
21） Ghosh N, et al. Reduced-intensity transplantation for lymphomas using haploidentical related
donors versus HLA-matched sibling donors: A center for international blood and marrow
transplant research analysis. J Clin Oncol 2016; 34: 3141-9.
22） Kanate AS, et al. Reduced-intensity transplantation for lymphomas using haploidentical related
donors vs HLA-matched unrelated donors. Blood 2016; 127: 938-47.
23） Ciurea SO, et al. Haploidentical transplant with posttransplant cyclophosphamide vs matched
unrelated donor transplant for acute myeloid leukemia. Blood 2015; 126: 1033-40.
24） Solomon SR, et al. Myeloablative vs reduced intensity T-cell-replete haploidentical
transplantation for hematologic malignancy. Blood Adv 2019; 3: 2836-44.
25） Bashey A, et al. Mobilized peripheral blood stem cells versus unstimulated bone marrow as a
graft source for T-cell-replete haploidentical donor transplantation using post-transplant
cyclophosphamide. J Clin Oncol 2017; 35: 3002-9.
26） Chiusolo P, et al. A modified post-transplant cyclophosphamide regimen, for unmanipulated
haploidentical marrow transplantation, in acute myeloid leukemia: A multicenter study. Biol
Blood Marrow Transplant 2018; 24: 1243-9.
27） Bazarbachi A, et. al. Haploidentical transplantation with post-transplantation cyclophosphamide
for T cell acute lymphoblastic leukemia: A report from the European Society for Blood and
Marrow Transplantation Acute Leukemia Working Party. Biol Blood Marrow Transplant 2020;
26: 936-42.
28） Nagler A, et.al. Outcome of haploidentical versus matched sibling donors in hematopoietic stem
cell transplantation for adult patients with acute lymphoblastic leukemia: A study from the Acute
Leukemia Working Party of the European Society for Blood and Marrow Transplantation. J
Hemotol Oncol 2021; 14: 53.
29） George B, et.al. Haploidentical transplantation is feasible and associated with reasonable
outcomes despite major infective complications-A single center experience from India.
Transplant Cell Ther 2022; 28: 45.e1-8.
30） Jaiswal SR, et al. Haploidentical peripheral blood stem cell transplantation with posttransplantation cyclophosphamide in children with advanced acute leukemia with fludarabine-,
busulfan-, and melphalan-based conditioning. Biol Blood Marrow Transplant 2016; 22: 499-
37